Structure-based classification predicts drug response in EGFR-mutant NSCLC
Jacqulyne Ponville Robichaux, Xiuning Le, R. S. K. Vijayan et al. · Nature · 2021
Abstract Epidermal growth factor receptor ( EGFR ) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC) 1–3 . Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations 4–6 . However, effective therapies have not been identified for additional EGFR mutations. Furthermore, the frequency and effects of atypical EGFR mutations on drug sensitivity are unknown 1,3,7–10 . Here we characterize the mutational landscape in 16,715 patients with EGFR -mutant NSCLC, and establish the structure–function relationship of EGFR mutations on drug sensitivity. We found that EGFR mutations can be separated into four distinct subgroups on the basis of sensitivity and structural changes that retrospectively predict patient outcomes following treatment with EGFR inhibitors better than traditional exon-based groups. Together, these data delineate a structure-based approach for defining functional groups of EGFR mutations that can effectively guide treatment and clinical trial choices for patients with EGFR -mutant NSCLC and suggest that a structure–function-based approach may improve the prediction of drug sensitivity to targeted therapies in oncogenes with diverse mutations.
Cited by 479 works. doi:10.1038/s41586-021-03898-1 Open-access PDF
Authors
- Jacqulyne Ponville Robichaux
- Xiuning Le
- R. S. K. Vijayan
- James Kevin Hicks
- Simon Heeke
- Yasir Y. Elamin
- Heather Yan Lin
- Hibiki Udagawa
- Ferdinandos Skoulidis
- Hai Thanh Tran
- Junqin He
- Fahao Zhang
- Monique B. Nilsson
- Lemei Hu
- Alissa Poteete
- Waree Rinsurongkawong
- Xiaoshan Zhang
- Chenghui Ren
- Xiaoke Liu
References
- Classification and Regression Trees.
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M